Event Date/Time: Sep 13, 2012 End Date/Time: Sep 14, 2012
Registration Date: Sep 12, 2012
Early Registration Date: Aug 10, 2012
Report as Spam

Description

NEXTBIO China 2012
From: 13 September 2012
To: 14 September 2012
Venue: Shanghai, China
Contact number: +86-21-61573930,61573919
Website: www.nextbio-china.com
Organizer: CPhI Conferences

Conference Background
Seizing opportunities from current regulatory environment and promising market to drive biologics/biosimilar forward!
Biologics and biosimilars are steadily growing as a new field of pharmaceutical biotechnology, analytical development and clinical research in Eruope, US and emerging markets like China. There are major shifts for large molecule drugs and small molecule drugs in the pharmaceutical industry :
 Across the globe, regulators continue to develop the approval pathways and guidance regarding biosimilars in EU, US and other semi-regulated markets like China.
 An aging portfolio of blockbuster drugs is approaching the end of patent protection.
 The number of new ‘small molecule’ drugs being approved continues to fall.
 The cost of R&D is rising.
 Big pharmas are actively looking elsewhere to fill product pipelines and meet growth targets from large molecule field.
 Economic barriers, along with regulatory complexity and uncertainty, are shaping the biologics industry into something entirely different from the generic small molecule pharmaceutical industry.

As China entering its 12th Five Year plan (2011-2015), a new era of biopharmaceutical industry in China is also coming. According to the Plan, the gross output value may reach 3 trillion RMB by 2015 with growth rate of 20% per year for biopharmaceutical industry. What then, will be the challenges be in order to be part of these opportunities? Regulatory complexities, market selection, technical development need to be clarified in this critical era for biopharmaceutical industry.

NEXTBIO China 2012 will bring together 100+ top-level business and technical executives from global and China pharmaceutical companies to discuss and showcase evolving biopharmaceutical landscape and solutions.

Why CPhI NEXTBIO is a “MUST ATTEND”?
 Global Conferences Local Solutions—Enjoy high-quality CPhI Conferences in China
 Research-driven Program—Benefiting from a comprehensive agenda from previous CPhI attendees and leading executives
 Outstanding Quality and Quantity—20+ speakers,100+ decision makers from 50+ leading and promising biopharmaceutical industry players
 Practical Case Studies—Hearing Real-life examples from leading industry players
 Informative Panel Discussions—Getting latest updates in bio regulatory, market and technology from leading experts
 On-spot Solution—Gaining clear guidance through Q&A sessions from experienced leaders
 Peer-to-Peer Networking—Exploring new contacts to maximize ROI through multiple networking opportunities: pre-event speed networking + networking break and luncheon + one 2 one VIP meeting

Who Should Attend?
By Job Title
CEOs, VPs, GMs, Directors and Heads of:
Biologics, Biotechnology, Biosimilar, R&D, Regulatory Affairs, Patents, Process Development, Clinical Testing,Pre-Clinical Testing, Formulations, Analysis and Testing, In-Licensing, Out-Licensing, Manufacturing, Quality Assurance / Quality Control

By Industry
Biopharma Manufacturers, iotechnology Manufacturers, Generic Pharma Manufacturers, Innovator Pharma Manufacturers, Analytical Laboratories, CRAMS, Equipment Suppliers, Ingredient and Material Suppliers

Conference Structure
Day One –13th Sep. 2012
Morning: Navigating regulatory complexities
Across the globe, regulators continue to develop the approval pathways and guidance regarding biosimilars in EU, US and other semi-regulated markets like China.
This session is designed to provide regulatory and non-regulatory pharma industry executives with comprehensive EU, US and China general regulatory registration procedure and specific registration rules.
Afternoon: Selecting profitable markets
Biologics industry is entirely different from the generic small molecule pharmaceutical industry. Blockbuster drug patents expire and IP infringements increase; The number of new ‘small molecule’ drugs being approved continues to fall; Big pharmas are looking elsewhere to fill product pipelines from large molecule field.
This session is designed to provide attendees with latest biopharma industry market information to maximize ROI.
Day Two–14th Sep. 2012
Optimizing Technology and Development Strategy
Biologics and biosimilars are steadily growing as a new field of pharmaceutical biotechnology, analytical development and clinical research in Eruope, US and emerging markets like China. The biopharma industry in China lacks of clear technical standard and regulatory environment while the 12th Five Year Plan (2011-2015) shows great potential for this industry.
Day Two is designed to equip attendees with technical optimization and development strategy in target design, mAb, pre-clinical, clinical, CMC, analytical field benchmark your strategies against the best practices in the industry.

Contact Information:
Tel: +86 21 6157 3930,6157 3919
Fax: +86 21 61577299
Email: conferencechina@ubm.com
Addr: 9th Floor, Ciro’s Plaza, West Nanjing Road, Shanghai, China.200003

Venue

100 Chang Liu Road,Pudong New Area , Shanghai, 200134 China
Shanghai
China
MORE INFO ON THIS VENUE

Restrictions

Types